Levels of CEACAM6 in Peripheral Blood Are Elevated in Patients with Plasma Cell Disorders: A Potential New Diagnostic Marker and a New Therapeutic Target?

摘要: Introduction. The prognosis of multiple myeloma is still unfavorable due to inherent characteristics the disease and often-delayed diagnosis widespread unspecific symptoms such as back pain fatigue. Therefore, a simple diagnostic blood test would be helpful speed up procedure in patients (pts.). Here, we evaluated value plasma levels carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6) peripheral bone marrow pts. with disorders healthy controls. Materials Methods. Immunoreactive CEACAM6 was determined () monoclonal gammopathy unknown significance (MGUS: 28/37), newly diagnosed (NDMM: 42/40), relapsed/refractory (RRMM: 25/23) by sandwich ELISA. Results. Median were significantly higher than those controls (healthy controls: 15.2 pg/ml (12.1-17.1); MGUS: 19.0 pg/ml (16.4-22.5); NDMM: 18.0 pg/ml (13.4-21.2); RRMM: 18.9 pg/ml (15.2-21.5); ). Plasma discriminated subjects from MGUS/NDMM (, 95% CI: 0.6-0.8); i.e.,  pg/ml has an 82% (95% 70-90) predictive probability for identification MGUS or NDMM. Moreover, RRMM NDMM (), suggesting role this progression. Conclusion. can noninvasively identify disorder should prospectively potential marker. high pts., might therapeutic target